Incanthera plc, the company focused on innovative technologies in dermatology and oncology, presents its interim results for the six months ended 30 September 2024.
The period under review saw enormous progression for the Company as we geared up operationally and corporately towards the launch of our luxury skincare range Skin + CELL.
With the support of both existing and new shareholders, we raised a total of £3.4 million in the period under review through an equity fundraise in June 2024 for £2.6 million and various warrant exercises through the period of £0.8 million.
This was invested into inventory across all five products in our Skin + CELL range, held with Frike Group, our contract manufacturer based in Zurich, Switzerland, ready for launch.
Following the period end, the Company announced on 26 November 2024 that it had received unsupported allegations from a third party, concerning a potential patent infringement in relation to the formulation of the Skin + Cell range of products. The Company considers the unsupported allegations to be without merit and is resolute in its commitment to a conclusion.
The Board of the Company remains confident for the future launch of its products and will continue to update the market, at its earliest opportunity.
Read the Half-year Report in full here
For further information please contact:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
+44 (0) 7831 675747
tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
simon.ward@incanthera.com
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
suzanne.brocks@incanthera.com
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/Liam Murray/Ed Downes
+44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Bob Pountney
+44 (0) 20 3650 3650/51
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com